Evidence map›Paper›PMID 35534152›Full record

ArticleThorax2023

Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis.

Luke M Kraven, Adam R Taylor, Philip L Molyneaux, Toby M Maher, John E McDonough, Marco Mura, Ivana V Yang, David A Schwartz, Yong Huang, Imre Noth and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Thorax, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Altered Metabolism in Idiopathic Pulmonary Fibrosis.Journal of cellular physiology · 2025
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. A Long and Winding Road: Drug Development in Idiopathic Pulmonary Fibrosis.American journal of respiratory and critical care medicine · 2024
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 3 countries.

Luke M Kraven *Department of Health Sciences, University of Leicester, Leicester, UK.ORCID 0000-0003-1908-6281
Adam R Taylor *Research & Development, GlaxoSmithKline, Stevenage, UK.
Philip L MolyneauxGuy's and St Thomas' NHS Foundation Trust, Royal Brompton and Harefield Hospitals, London, UK.
Toby M MaherGuy's and St Thomas' NHS Foundation Trust, Royal Brompton and Harefield Hospitals, London, UK.
John E McDonoughDivision of Pulmonary, Critical Care & Sleep Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Marco MuraDivision of Respirology, Western University, London, Ontario, Canada.ORCID 0000-0002-2159-7083
Ivana V YangDepartment of Medicine, University of Colorado, Denver, Colorado, USA.
David A SchwartzDepartment of Medicine, University of Colorado, Denver, Colorado, USA.
Yong HuangDivision of Pulmonary & Critical Care Medicine, University of Virginia, Charlottesville, Virginia, USA.
Imre NothDivision of Pulmonary & Critical Care Medicine, University of Virginia, Charlottesville, Virginia, USA.
Shwu Fan MaDivision of Pulmonary & Critical Care Medicine, University of Virginia, Charlottesville, Virginia, USA.
Astrid J Yeo *Research & Development, GlaxoSmithKline, Stevenage, UK.
William A Fahy *Research & Development, GlaxoSmithKline, Stevenage, UK.
R Gisli Jenkins *National Heart and Lung Institute, Imperial College London, London, UK.ORCID 0000-0002-7929-2119
Louise V Wain *Department of Health Sciences, University of Leicester, Leicester, UK lvw1@le.ac.uk.
GlaxoSmithKline (United Kingdom) · GBUniversity of Virginia · USUniversity of Colorado Denver · USUniversity of Leicester · GBGuy's and St Thomas' NHS Foundation Trust · GBNational Institute for Health Research · GBUniversity of Southern California · USWestern University · CAYale University · US

Funding

Mechanisms of Familial Pulmonary FibrosisP01HL092870 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BLACKWELL, TIMOTHY S. · 2010 to 2020
$21.6M
Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)R01HL097163 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI FINGERLIN, TASHA E., SCHWARTZ, DAVID ALBERT · 2009 to 2018
$16.4M
Targeting early events in MUC5B-driven lung injury and fibrosisP01HL162607 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI David Albert Schwartz · 2023 to 2026
$12.4M
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyUH3HL145266 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARTINEZ, FERNANDO J, NOTH, IMRE · 2021 to 2025
$11.6M
MUC5B, a novel therapeutic target for Idiopathic Pulmonary Fibrosis (IPF)UH3HL123442 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2016 to 2018
$4.8M
Preclinical Pulmonary Fibrosis, an opportune rare disease cohortUH3HL151865 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2022 to 2025
$4.3M
Molecular Determinants of Usual Interstitial Pneumonia (UIP)R01HL158668 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI David Albert Schwartz, Ivana V Yang · 2022 to 2026
$3.5M
Architectural structure and regulation of TOLLIP in IPFR01HL130796 · NHLBI · UNIVERSITY OF VIRGINIA · PI NOTH, IMRE · 2016 to 2019
$3.1M
Preclinical Pulmonary Fibrosis, an opportune rare disease cohortUG3HL151865 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2020 to 2021
$1.7M
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyUG3HL145266 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARTINEZ, FERNANDO J, NOTH, IMRE · 2019 to 2019
$977k
lncRNAs, Linking Genetic Susceptibility to Molecular Phenotype in IPFI01BX005295 · VA · VA EASTERN COLORADO HEALTH CARE SYSTEM · PI David Albert Schwartz · 2022 to 2026
–
BLRD VA I01 BX005295HSRD VA CDA 13-017Medical Research Council MR/V00235X/1NHLBI NIH HHS P01 HL092870NHLBI NIH HHS P01 HL162607NHLBI NIH HHS R01 HL097163NHLBI NIH HHS R01 HL130796NHLBI NIH HHS R01 HL158668NHLBI NIH HHS UG3 HL145266NHLBI NIH HHS UG3 HL151865NHLBI NIH HHS UH3 HL123442NHLBI NIH HHS UH3 HL145266NHLBI NIH HHS UH3 HL151865
6 · The paper itself

Abstract

backgroundConsiderable clinical heterogeneity in idiopathic pulmonary fibrosis (IPF) suggests the existence of multiple disease endotypes. Identifying these endotypes would improve our understanding of the pathogenesis of IPF and could allow for a biomarker-driven personalised medicine approach. We aimed to identify clinically distinct groups of patients with IPF that could represent distinct disease endotypes.

methodsWe co-normalised, pooled and clustered three publicly available blood transcriptomic datasets (total 220 IPF cases). We compared clinical traits across clusters and used gene enrichment analysis to identify biological pathways and processes that were over-represented among the genes that were differentially expressed across clusters. A gene-based classifier was developed and validated using three additional independent datasets (total 194 IPF cases).

findingsWe identified three clusters of patients with IPF with statistically significant differences in lung function (p=0.009) and mortality (p=0.009) between groups. Gene enrichment analysis implicated mitochondrial homeostasis, apoptosis, cell cycle and innate and adaptive immunity in the pathogenesis underlying these groups. We developed and validated a 13-gene cluster classifier that predicted mortality in IPF (high-risk clusters vs low-risk cluster: HR 4.25, 95% CI 2.14 to 8.46, p=3.7×10

interpretationWe have identified blood gene expression signatures capable of discerning groups of patients with IPF with significant differences in survival. These clusters could be representative of distinct pathophysiological states, which would support the theory of multiple endotypes of IPF. Although more work must be done to confirm the existence of these endotypes, our classifier could be a useful tool in patient stratification and outcome prediction in IPF.

Indexed as

Idiopathic Pulmonary FibrosisTranscriptomeBiomarkersCluster AnalysisGene Expression ProfilingHumansBiomarkersidiopathic pulmonary fibrosis

Identifiers

PMID35534152
PMCPMC9643664
OpenAlexW4280553512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.